Back to search results

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Chronic Lymphocytic Leukemia · Richter Syndrome · Small Lymphocytic Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

    Contact: Study coordinator (Bita Fakhri, MD, MPH) · bfakhri@stanford.edu · 617-650-6205
    Contact: Principal Investigator (Bita Fakhri, MD, MPH)

  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Paul J. Hampel, MD)

  • Washington University School of Medicine, St Louis, Missouri, United States

Study leads

  • Paul J. Hampel, MD

    Principal Investigator

    Mayo Clinic in Rochester

View source on ClinicalTrials.gov(opens in a new tab)